На этой странице представлены анонсы статей. Полный текст статей доступен членам МООСБТ (Как вступить в МООСБТ).
«Российский журнал боли» №1 (42), 2014 г.
«Российский журнал боли» издается с 2010 г. при поддержке РОИБ и выходит с периодичностью четыре номера в год (один раз в три месяца). В каждом номере публикуются статьи авторов-соискателей ученой степени кандидата медицинских наук. В данной публикации представлены Материалы XX Российской научно-практической конференции с международным участием «БОЛЕВЫЕ СИНДРОМЫ: СОВРЕМЕННЫЙ ВЗГЛЯД НА ДИАГНОСТИКУ И ЛЕЧЕНИЕ» 14–16 мая 2014 г. Астрахань.
«Российский журнал боли» 2014, № 2 (43), 1–52
«Российский журнал боли» издается с 2010 г. при поддержке РОИБ и выходит с периодичностью четыре номера в год (один раз в три месяца). В каждом номере публикуются статьи авторов-соискателей ученой степени кандидата медицинских наук.
Blepharospasm is a focal cranial dystonia, which could be idiopathic in origin or secondary to an underlying disorder that commonly impairs quality of life. Botulinum toxin (BoNT) injections have become the treatment of choice; however, a less favorable response to BoNT is expected in secondary blepharospasm. No studies have been conducted comparing outcomes between blepharospasm cohorts. We therefore aim to compare BoNT outcomes in primary and secondary blepharospasm subjects.
Автор: Jiewen Dai, Hongbo Yu, Min Zhu, Steve Guofang Shen
Injection of botulinum toxin A in lateral pterygoid muscle as a novel method for prevention of traumatic temporomandibular joint ankylosis
Temporomandibular joint (TMJ) ankylosis can restrict the mandibular movement, followed by resulting in numerous problems. To understand the mechanism of TMJ ankylosis (TMJA) and prevent the generation of TMJA is urgent necessary. Although many factors contribute to it, trauma is the most common cause of TMJA. The mechanisms of TMJA are still unclear, and the distraction osteogenesis of the lateral pterygoid muscle (LPM) may play an important role. Injection of very small amounts of botulinum toxin type A (BTA) can temporarily block the muscle’s impulse and has been revealed to be an effective treatment method for many temporomandibular disorders.
Автор: Larissa Bittencourt da Silva, Dolarose Kulas, Ali Karshenas, Brian E. Cairns, Flemming W. Bach, Lars Arendt-Nielsen and Parisa Gazerani
The effect of botulinum neurotoxin type A (BoNTA) on glutamate-evoked temporalis muscle pain and vasomotor responses was investigated in healthy men and women over a 60 day time course. Subjects participated in a pre-BoNTA session where their responses to injection of glutamate (1 M, 0.2 mL) and saline (0.2 mL) into the temporalis muscles were assessed. On Day 1, BoNTA (5 U) was injected into one temporalis muscle and saline into the contralateral temporalis muscle, in a randomized order. Subjects then received intramuscular injections of glutamate (1 M, 0.2 mL) into the left and right temporalis muscles at 3 h and subsequently 7, 30 and 60 days post-injection of BoNTA.
Pain intensity, pain area, and neurogenic inflammation (skin temperature and skin blood perfusion) were recorded. Prior to BoNTA treatment, glutamate evoked significantly greater pain and vasomotor reactions (P < 0.001) than saline. BoNTA significantly reduced glutamate-evoked pain intensity (P < 0.05), pain area (P < 0.01), skin blood perfusion (P < 0.05), and skin temperature (P < 0.001). The inhibitory effect of BoNTA was present at 3 h after injection, peaked after 7 days and returned to baseline by 60 days.
Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders.
To determine the amount of BoNT/A protein present in pharmaceutical preparations of Botox®, Dysport®, and Xeomin®, which are identical with Vistabel®, Azzalure®, and Bocouture®, respectively.
Автор: Hashem Shemshadi, MD.; Mojtaba Azimian, MD; Ahmad Ali Akbari Kamrani, MD.
In this study, we examined the effect of botulinum toxin A (BTA) on chronic allergic rhinitis (CAR). We tested the effects of BTA, applied to an intranasal sponge, on patients who had CAR for a minimum of three years and had been treated unsuccessfully with conventional medications.
Автор: Орлова О.Р., д.м.н. профессор, президент МООСБТ
Это первый в России журнал о косметологии и эстетической медицине, издающийся с 1995г. В 2015г. журнал отметит юбилейную дату - 20 лет со дня основания.
KOSMETIK international распространяется не только на территории России. Среди читателей немало и зарубежных подписчиков. Как один из самых крупных тематических журналов сфере науки о красоте, KOSMETIK international внес немалый вклад в развитие ботулинотерапии в России.
Ежеквартальное информационно-образовательное издание «Вестник ботулинотерапии МООСБТ».
Автор: Jennifer Hong MD, Perry A. Ball MD, Gilbert J. Fanciullo MD
Patients with medically refractory headache disorders are a rare and challenging-to-treat group. The introduction of peripheral neurostimulation (PNS) has offered a new avenue of treatment for patients who are appropriate surgical candidates. The utility of PNS for headache management is actively debated. Preliminary reports suggested that 60–80% of patients with chronic headache who have failed maximum medical therapy respond to PNS. However, complications rates for PNS are high.
Материалы Консенсуса Международного экспертного совета с комментариями членов Российского экспертного совета.
Ежеквартальное информационно-образовательное издание «Вестник ботулинотерапии МООСБТ».
Автор: Dirk Dressler, Gerd Mander, Klaus Fink
Measuring the potency labelling of onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in an LD50 assay (ENG)
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling varies vary amongst different BT drugs. One reason for this may be differences in the LD50 assays applied. When five unexpired batches of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®)) are compared in the Xeomin(®) batch release assay, the potency variability of both BT drugs fell within the range allowed by the European Pharmacopoiea. Statistical analyses failed to detect differences in the potency labelling of both products.
Stability of botulinum neurotoxin type A, devoid of complexing proteins (ENG)
Botulinum toxin type A is a complex composed of the biologically active neurotoxin, several hemagglutinins and other nontoxic proteins. After intramuscular injection these complexing proteins do not have any therapeutic effect. However, they protect the neurotoxin from harsh environmental conditions, e.g., low intragastral pH after oral ingestion. NT201, a BoNT/A drug product devoid of complexing proteins was tested in real-time and accelerated stability studies. NT201 was found to be stable without refrigeration for 48 months and even not affected by short-term temperature stress up to 60°C, demonstrating that complexing proteins are not required for the stability of BoNT/A preparations.
Автор: Joohi Jimenez-Shahed
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins (ENG)
These studies have also suggested that incobotulinumtoxinA is associated with a lower risk for stimulating antibody formation than onabotulinumtoxinA. In phase 3 noninferiority trials, incobotulinumtoxinA demonstrated significant improvements in CD and BSP symptoms in both primary and secondary measures, compared with baseline, and met criteria for noninferiority versus onabotulinumtoxinA. In placebo-controlled trials, incobotulinumtoxinA also significantly improved the symptoms of CD and BSP, with robust outcomes in both primary and secondary measures. The use of incobotulinumtoxinA has been well tolerated in all trials, with an adverse event profile similar to that of onabotulinumtoxinA.
Автор: Santamato A, Micello MF, Panza F, Fortunato F, Pilotto A, Giustini A, Testa A, Fiore P, Ranieri M, Spidalieri R.
Toward an epidemiology of poststroke spasticity (ENG)
Poststroke spasticity (PSS)-related disability is emerging as a significant health issue for stroke survivors. There is a need for predictors and early identification of PSS in order to minimize complications and maladaptation from spasticity. Reviewing the literature on stroke and upper motor neuron syndrome, spasticity, contracture, and increased muscle tone measured with the Modified Ashworth Scale and the Tone Assessment Scale provided data on the dynamic time course of PSS. Prevalence estimates of PSS were highly variable, ranging from 4% to 42.6%, with the prevalence of disabling spasticity ranging from 2% to 13%. Data on phases of the PSS continuum revealed evidence of PSS in 4% to 27% of those in the early time course (1-4 weeks poststroke), 19% to 26.7% of those in the postacute phase (1-3 months poststroke), and 17% to 42.6% of those in the chronic phase (>3 months poststroke).
Автор: Florian Heinena, Kaat Desloovere , A. Sebastian Schroeder and others